Stocklytics Platform
Asset logo for symbol XFOR
X4 Pharmaceuticals
XFOR58
$0.39arrow_drop_down1.46%-$0.00
Penny Stock
Asset logo for symbol XFOR
XFOR58

$0.39

arrow_drop_down1.46%

Performance History

Chart placeholder
Key Stats
Open$0.30
Prev. Close$0.27
EPS0.12
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$57.99M
LOWHIGH
Day Range0.29
0.48
52 Week Range0.26
1.60
Ratios
Revenue-
EBITDA Margin %-
EPS0.12

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About X4 Pharmaceuticals (XFOR)

X4 Pharmaceuticals Inc (XFOR) is a biotechnology company that focuses on the discovery and development of novel small molecule therapeutics for the treatment of rare diseases. The company's lead product candidate, X4P-001, is being evaluated in multiple clinical trials for the treatment of various rare primary immunodeficiency diseases. X4P-001 is a potential first-in-class oral therapy that targets the CXCR4 pathway, which plays a critical role in the immune system and is involved in the pathogenesis of several rare diseases. The company's pipeline also includes X4P-002, a potential treatment for solid tumors, and X4P-003, a potential treatment for hematologic malignancies.
X4 Pharmaceuticals Inc's stock price has experienced significant fluctuations over the past year. As of the latest available data, the stock is trading at $10.50 per share. The 52-week range for XFOR stock is $7.25 to $13.50. The stock has a market capitalization of approximately $200 million. In terms of valuation, X4 Pharmaceuticals Inc has a PEG ratio of N/A, as earnings growth estimates are not available at this time. In comparison to the industry, XFOR stock has performed relatively well, outperforming some of its peers. However, it is important to note that investing in biotechnology stocks involves inherent risks and investors should carefully consider their investment objectives and risk tolerance before investing in X4 Pharmaceuticals Inc or any other biotechnology company.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Paula Ragan Ph.D.
Headquarters
Boston
Employees
40
Exchange
NASDAQ
add X4 Pharmaceuticals to watchlist

Keep an eye on X4 Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is X4 Pharmaceuticals 's (XFOR) price per share?

The current price per share for X4 Pharmaceuticals (XFOR) is $0.39. The stock has seen a price change of -$0.01 recently, indicating a -1.46% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for X4 Pharmaceuticals (XFOR)?

For X4 Pharmaceuticals (XFOR), the 52-week high is $1.6, which is 310.26% from the current price. The 52-week low is $0.27, the current price is 47.17% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is X4 Pharmaceuticals (XFOR) a growth stock?

X4 Pharmaceuticals (XFOR) has shown an average price growth of -4.94% over the past three years. It has received a score of 1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying X4 Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is X4 Pharmaceuticals (XFOR) stock price performance year to date (YTD)?

As of the latest data, X4 Pharmaceuticals (XFOR) has a year-to-date price change of -55.79%. Over the past month, the stock has experienced a price change of -29.96%. Over the last three months, the change has been -38.32%. Over the past six months, the figure is -60.05%. Looking at a longer horizon, the five-year price change stands at -97.03%.
help

Is X4 Pharmaceuticals (XFOR) a profitable company?

X4 Pharmaceuticals (XFOR) has a net income of -$101.17M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -6.02K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$107.52M. Furthermore, the EBITDA is -$123.18M.
help

What is the market capitalization of X4 Pharmaceuticals (XFOR)?

X4 Pharmaceuticals (XFOR) has a market capitalization of $67.99M. The average daily trading volume is 0.39, indicating the stock's liquidity and investor engagement.

News

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
X4 PHARMACEUTICALS
MAVORIXAFOR
CHRONIC NEUTROPENIA
PHASE 2 TRIAL
ABSOLUTE NEUTROPHIL COUNT
G-CSF
Nov 13, 2024

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
HEALTH
CLINICAL STUDY
Jun 27, 2024

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MAJOR SHAREHOLDER ANNOUNCEMENTS
Jun 3, 2024

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
CALENDAR OF EVENTS
PRODUCT / SERVICES ANNOUNCEMENT
CONFERENCE CALLS/ WEBCASTS
May 29, 2024

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
FINANCING AGREEMENTS
HEALTH
May 9, 2024

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
EARNINGS RELEASES AND OPERATING RESULTS
May 7, 2024

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level